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Corrélation entre type de Human Papilloma Virus et récidive 
après traitement chirurgical de condylomes acuminés anaux 
Le condylome acuminé anal (CAA), transmis par contact sexuel, résulte d'une 
infection par Human Paptlloma Vtrus (HPV). Son traitement chirurgical est 
grevé d'un taux de récidive de 4-29%. Le but de cette étude était d'identifier 
une éventuelle corrélation entre type d'HPV présent dans les CAA excisés 
chirurgicalement et taux de récidive de la maladie. 
Cette étude rétrospective porte sur 140 patients opérés au Centre Hospitalier 
Universitaire Vaudois de CAA, entre 1990 et 2005. Le diagnostic lésionnel a 
été confirmé par un examen histomorphologique. Le(s) type(s) d'HPV 
présent(s) dans ces lésions a été déterminé par Polymerase Chain Reaction 
(PCR). Les patients ont donné leur accord à cette analyse et complété un 
questionnaire. Une éventuelle corrélation entre récidive de CAA, type d'HPV 
et status HIV a été recherchée. 
HPV 6 et 11 sont les virus les plus fréquemment découverts (51 % et 28%, 
respectivement) chez les 140 patients (123H/17F). Trente-cinq (25%) d'entre 
eux ont présenté une récidive. HPV 11 était présent chez 19 (41%) sujets. 
Ceci est statistiquement significatif (P<0.05), en comparaison aux autres 
HPVs. Il n'y a par contre pas de différence significative entre la fréquence de 
récidive des 33 (24%) patients HIV-positifs et le reste du collectif. 
HPV 11 est donc associé à un taux de récidive de CAA significativement 
.élevé. Un suivi strict des patients atteints est nécessaire pour identifier une 
récidive et la traiter sans délai, notamment lorsque HPV 11 est présent. Ces 
résultats innovateurs soulèvent la question de la nécessité de pratiquer une 
typisation virale systématique sur les lésions excisées. La justification d'une 
telle attitude demande toutefois encore d'être confirmée. 
of the lesion(s) and patient preference. It consisted of a com-
prehensive pe1ianal, anal, and rectoscopie examination fol-
Iowed by excision of ail visible warts starting with the perianal 
region. An en bloc excision was achieved with scissors with a 
free margin of normal tissue. The site of excision was then 
systematically cauterized with diathermy. Resorptive sutures 
were only exceptionally used on perianal skin or mucosa, to 
improve the scarring process. If disease was extensive or con-
sequent anal stenosis feared, excision was carried out by se-
quential procedures with an intermittent maximum delay of 6 
weeks. 
Histologie Analysis 
Ali specimens were submitted to standard histologie 
examination, to confirm diagnosis of condylomata acuminata 
(S.Y., H.B.). The most representative lesions were used for 
HPV genotyping. 
HPV Genotyping 
DNA was purified from fresh biopsy samples or paraf-
fin-embedded material using the Magna Pure DNA isolation kit 
(N°3003990, Roche, Rotkreuz, Switzerland) on the Magna LC 
robot (Roche). Negative controls accompanied each set of 
DNA extractions assess contamination. Typing was performed 
at the Institute of Microbiology as part of its routine diagnostic 
testing using accredited procedures (ENI 7025) that will be 
published elsewhere (Estrade et al., In press). Briefly, HPV 
DNA was detected by polymerase chain reaction (PCR) and 
genotyped by reverse line blot hybridization (RLBH). PCR was 
performed with 5 µL DNA in triplicate 50 µL reactions using 
the PGMY primers, according to Gravitt et al.,24 with slight 
modifications. The PGMYI J primers and one of the HLA 
primers were biotinylated to detect the amplicon in the geno-
typing by RLBH. PGMY primers were used at 80 nM, HLA at 
40 nM in 1 X PCR buffer II (Applied Biosystems, Rotkreuz. 
Switzerland), 0.2 mmol/L dNTPs, 1.5 mmol/L MgCl2, and l .25 
units of AmpliTaq Gold (Applied Biosystems). HLA-DQA 
primers25 were used as an internai standard to assess the quality 
of the DNA and absence of PCR inhibitors. Positive controls 
(HPV16 DNA from Caski cells) and negative controls (PCR-
grade water) were systematically analyzed to ensure appropri-
ate sensitivity of the reaction (at least 100 copies ofHPV DNA) 
and absence of contamination, respectively. Following PCR. 5 
µL of each reaction were analyzed by gel electrophoresis and 
staining with ethidium bromide. Samples were considered in-
formative if the HLA or the HPV DNA fragment could be 
detected. RLBH was performed on positive samples by RLBH 
with a miniblotter (MN 45, Immunetics, Boston) essentially as 
described by Kaufhold et al.26 using a panel of 31 HPV type-
specific probes (high-risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56. 
58, 59, 68, 69, MM4 [Type 82), and MM9 [Type 73]: low-risk: 
6, 11, 34, 40, 42, 44, 53, 54. 57, 70, and MM8 [Type 84); 
undetermined-risk: 26, 55, 66, and MM7 [Type 83)) arrayed on 
a reusable, negatively-charged nylon membrane. This proce-
dure has been validated in the course of the first World Health 
Organization international collaborative study on detection of 
human papillomavirus DNA.27 To identify types not repre-
sented in the panel of probes, sequencing was performed on 
PCR-positive/hybridization-negative samples with sequencers 
from Applied Biosystems using the Big Dye Terminator chem-
istry (BDT v.1.1, Applied Biosystems) and PGMYl 1 primers. 
Sectioning of the paraffin block was donc with single-
use disposable blades to eliminate the risk of intersample 
contamination. Standard procedures to avoid PCR contamina-
Anal 
tion were strictly followed: work was done in separate labora-
tories (pre- and post-PCR analysis). 
Definition 
Recurrence was defined as the advent of new lesion(s) 
within 12 months after curative surgery. This delay was chosen 
arbitrarily, as the literature is vague about this definition. Fur-
thermore, in patients without visible warts after treatment, there 
is no way to verify whether the viral infection has becn com-
pletely cleared or whether it is present and latent, at the site of 
previous resection or on adjacent mucosa.2 As clinical warts 
depend upon the presence of HPV, it is difficult to determine 
whether ACA will recur in this context. 
Follow-Up 
Two groups of patients were defined: those without and 
those with recurrent disease. New lesions were surgically excised 
and diagnosis of ACA was confirmed by histology. Recurrencc 
rates and tiJne to recurrence after surgery were calculated. 
Statistical Analyses 
To compare patients' distribution, Pearson homogeneity 
test (x2) was used. When theoretical numbers were <5, the 
Monte-Carlo simulation test was used with 2000 simulations.28 
Wilcoxon test was performed for age. Statistical analysis was 
performed with R software (version 2.2.1).29 To fulfill basic 
statistical rules for analysis and thus to obtain independent data, 
only the first lesion was considered. Significance was assumed 
to occur at P <0.05. 
RESULTS 
One hundred forty consecutive patients were included in 
this study. Median age was 35.3 years (SD = 11.7). Of the 123 
(88%) males, 40 (32%) declared themselves to be heterosexu-
als, 73 (60%) homosexuals, and 10 (8%) bisexuals. Of the 17 
(12%) females, 16 (94%) were heterosexual and 1 (6%) was 
bisexual. 
Recurrence occurred in 35 (25.0%, 1 female and 34 
males) patients, 21 to 357 days after curative surgery (median 
120 days). Median age of the nonrecurrent and recurrent group 
was 36.4 (SD = 12.4) and 31.9 (SD 1 = 8.7), respectively. Age 
and gender did not represent a risk factor for recurrence 
(P >0.05). 
Median follow-up was 32 months (SD = 35.4); this 
included both the clinical follow-up and the information pro-
vided in the retumed questionnaires (of the questionnaires sent 
out, 71 % were retumed). 
HPV Types 
Initially, 144 patients had histologically confirmed pri-
mary ACA; 4 of tbem were excluded because conclusive typing 
of HPV was not possible (no DNA could be amplified). fn the 
remaining 140 (123 M/17 F) patients, 17 different HPV types 
(2a, 6, li, 16, 18, 27, 31, 40, 44, 45. 51, 53, 58, 59, 6 l. 66, and 
68) were id::ntified. 
HPV 6 and 11 were the most frequently encountered 
viruses, representing 84 (51 % ) and 46 (28%) out of the 165 
HPV s, respectively. Recurrence was detected in 16 cases with 
HPV 6 (P >0.05) and in 19 cases with HPV 11 (P <0.05). As 
a result of the high prevalence of HPV 6 and 11. data are stable 
and classic x2 test has been used. 
Other viruses were rarely present, respectively identified 
once (HPV 2a, 27, 31, 40, 58, and 61), twice (HPV 44, 45, 59, 
and 68), thrice (HPV 51, 53, and 66), 5 times (HPV 18), and 8 
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TABLE 1. Association Between HPV Type and Recurrent 
Disease 
Nonrecurrent 
HPY Disease n (%) 
2 1 ( l.0) 
6 68 (64.8) 
li 27 (25.7) 
16 8 (7.6) 
18 4 (3.8) 
27 1 (1.0) 
31 l ( 1.0) 
39 1 (1.0) 
44 l ( l.0) 
45 0 (0.0) 
51 2 ( 1.9) 
53 3 (2.9) 
58 0 (0.0) 
59 0 (0.0) 
61 1 (1.0) 
66 3 (2.9) 
68 2 ( 1.9) 
Negative 6 (5.7) 
*x2 with simulation. 
tc1assical x2. 
Recurrent 
Disease n (%) 
0 (0.0) 
16 (45.7) 
19 (54.3) 
0 (0.0) 
l (2.9) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
1 (2.9) 
2 (5.7) 
1 (2.9) 
0 (0.0) 
1 (2.9) 
2 (5.7) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
l (2.95) 
HPV indicates Human Papilloma Virus. 
p 
l.000* 
o.o73t 
o.004t 
0.203* 
1.000* 
1.000* 
1.000* 
1.000* 
1.000* 
0.051* 
J.000* 
0.570* 
0.253* 
0.065* 
1.000* 
0.582* 
1.000* 
0.672* 
times (HPV 16). For these rarely identified viruses, the Monte-
Carlo simulation test28 was used with 2000 simulations. 
Seven among 140 (5%) patients had no HPV type iden-
tified in the surgically excised specimen. One of them presented 
with recurrence. Details about association between recmTence 
and HPV types are reported in Table 1. 
Mixed Infection (More Than 1 Virus ldentified 
in 1 Single ACA) 
One hundred five among 140 (75%) patients were in-
fected by a single HPV, and 24 of them recurred. Twenty-eight 
among 140 (20%) patients presented a mixed infection, and 10 
of them recurred. When compared, neither none, single nor 
mixed infections were associated with statistically higher re-
currence rates P >0.05 (Table 2). 
Among the 10 patients with mixed infections which 
recurred, 9 contained HPV 11, and 1 did not. There was a 
significant correlation between mixed infection associating 
HPV 11 and recurrence compared to mixed infection without 
HPY 11 (P <0.05). 
HIV Status 
Thirty-three (24%) patients were HIV-positive, 97 
(69%) HIV-negative, whereas in 10 (7%) patients HIV status 
TABLE 2. Distribution of Recurrence Between None, Single, 
and Mixed Infections 
Virus 
None 
Single 
Mixed 
Total 
Nonrecurrent 
Disease n 
6 (5.7) 
81 (77.J) 
18(17.2) 
105 
*x2 with simulation. 
Recurrent 
Disease n (%) 
l (2.8) 
24 (68.6) 
10 (28.6) 
35 
p 
0.351* 
was not known. These 10 patients were not included in the 
association test between HIV and recurrent disease. Pive of the 
33 HIV-positive patients, whereas 30 of the 97 HIV-negative, 
presented with recurrence. Showing that HIV-positive status 
was not a risk factor for recurrence (P >0.05). However, the 
CD4 counts of HIV-positive patients were not known at the 
point of surgery. 
DISCUSSION 
Possible correlation between HPV type and recurrence 
of ACA has been little studied and remaîns debatable. Never-
theless, ACA are very frequent and, apart from HIV seropos-
îtivity, no other specific risk factor for recurrent ACA has been 
described in the literature. 
For the purposes of this article, to obtain independent 
data and to fulfil basic statistical rules for analysis, only the first 
lesion was considered. According to the definition of recur-
rence (mentioned in Definition under Materials and Methods), 
only recurrences within 1 year were considered. Interestingly, 
the earliest clinical wart described after the period of 12 months 
was at 20 months. This "8-month-gap" suggests that the defi-
nition currently used can be considered as adequate. Unfortu-
nately, no other data were available to supp01t this statement. 
However, it is noted that Nathan et al.3° also considered their 
patients as cured after a 12-months disease-free period after 
Jaser ablative therapy for HPV-associated anal canal disease. 
Among the 140 patients, 7 (5%) had no HPV identified. 
These patients should arguably be excluded. However, 1 of 
these 7 patients presented with recurrence. Ali 7 have therefore 
been included in the study, considering that this situation could 
paradoxically represent a risk factor for recurrence. However, 
as expected, statistical analysis showed that absence of viral 
DNA was indeed not a risk factor. Because of this singular 
patient, ail 7 were nevertheless included in the analysis, even 
though they made the case for HPV 11 weaker. 
In the current study, neither age nor gender represented 
a risk factor for recurrence. Nevertheless, they both verge on 
statistical significance (P = 0.080 and 0.064, respectively). 
Median age of the recurrence group was only 4.5 years 
younger than the nonrecurrence group. Thus, the population 
cannot be divided in 2 specific separate groups as the ages are 
too close. This is also supported by Nathan et al.30 who showed 
that outcome of laser treated HPV-associated anal canal dis-
eases were not affected by age. 
The distribution of the 34/l recurrent males/female 
makes the genders difficult to compare and the P value of 0.080 
difficult to analyze. 
HPV 6 and 11 were the most frequently encountered 
viruses. This is consistent with the results published by Dupin31 
who showed that mucosal HPV 6 and 11 are the types most 
frequently found in patients with genital warts or condylomata 
acuminata. This deduction is also supported by Kreuter et al.32 
The whole of their cohort of patients excised by surgery for 
intraanal condylomata carried HPV 6 or 11. 
HPV 11 was associated with statistically higher recur-
rence rates, when present alone and also in mixed infections. 
Venturoli et al.33 observed that the residual or recurrent disease 
in 72 women treated by surgery for HPV infection with per-
sistence of the high-risk HPV 16 and/or 18 was higher ( 82.4%) 
than in women with persistence of at least 1 of HPV Type 31, 
33, 35, 45, 52, and 58 (66.7%) and at least 1 of HPV Type 26, 
39, 51, 53, 56, 59, 66, 68. 73, and 82 (14.3%). This is the only 
study that correlated recu!1'ence with HPV type. However, 
these authors concentrated on high-risk HPVs and only on 
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women. They did not include low- and intermediate-risk HPVs, 
particularly HPV 6 and 11. Our patients' recurrences cannot be 
compared with Venturoli, or with the literature, as other similar 
cohorts have not been published. 
Che et al. 34 also studied HPV and recurrence of condy-
lomata but they did not mention exactly where the lesions 
recurred: whether vagina, penis, or anus. Their work concen-
trated on HPV DNA loads rather than HPV typing. They found 
HPV Type 6 or 11 in 98.4% of cases (recurrent or not) but used 
a Fluorescence Quantitative PCR Diagnostic Kit, which does 
not differentiate HPV 6 from 11. Kreuter et aJ.32 studied the 
HPV DNA load by HIV-infected men treated with 5% imi-
quimod suppositories after surgical ablation, using electrocau-
tery, of intraanal condylomata acuminata. They showed that the 
suppositories Jed to a sharp decrease in HPV DNA Joad and 
concluded that larger clinicaJ trials are needed to find out 
whether relapse rates with the use of imiquimod after surgery 
are significantly lower than with surgery aJone. Only 7 patients 
were incJuded in their study and they also did not anaJyze the 
correJation between HPV type and recurrence. So, neither of 
these 2 studies can readiJy be compared with our results in 
terms of HPV typing and recurrence. 
The present series shows that HIV seropositivity does 
not apparently influence ACA recurrence as suggested by 
Stevens et al. 35 EpidemioJogic studies have shown that HIV 
seropositivity and other conditions are risk factors for HPV 
infection among women.2·3 Nothing was said about risk factors 
for recurrence. Other studies need to be petformed to determine 
if HIV seropositivity really acts as an independent risk factor 
on the prevalence of HPV infection and recurrent disease. The 
low recurrence rate demonstrated among HIV-positive patients 
suggests that our surgical technique was of importance: en bloc 
resection with a free margin of normal tissue ensured clearance, 
and diathermy, systematically used to obtain hemostasis, pre-
vented any residuaJ virus frorn being left on the resection site. 
CD4 count of the patients was not known at the time of surgical 
treatment, which makes their reaJ immune competence difficult 
to detetmine. However, SancJemente et al.36 showed in a series 
of 37 patients that the efficacy of 5% imiquimod in HIV-
positive male patients suffering from anogenital warts or anal 
intraepithelial neoplasia was not inftuenced by patients' CD4 
count, HIV viral load, or HPV viral load, meaning that recur-
rence was not inftuenced by HIV status. This is consistent with 
our series. 
A severity scoring system for condylomata presented at 
the American Society of Colon and Rectal Surgeons 2004 
Meeting suggested a scale of 0 to 5 applied to 3 areas: the 
intraanaJ, perianal, and extraanal regions.35 The 3 scores were 
added to create the condyloma scoring system (maximum 15) 
as a predictor of recurrence. The Jack of information in our 
retrospectively analyzed cohort unfortunately did not allow use 
of this algorithm. 
We found HPV 6 and 11 to be the most frequently 
identified viruses. Compared with ail others, HPV 11 seemed to 
change the course of the disease with statistical significance 
(P == 0.004) and it confers an increased risk of recurrent ACA. 
Routine clinical HPV typing remains, however, questionable. 
In the absence of any proven benefit, the additionaJ cost of 
investigation and treatment is difficult to justify when based 
soJely on analysis of a retrospective cohort of 140 patients 
extending over a period of 15 years. At this point, we cannot 
yet recommend systematic HPV typing, its reJevance not hav-
ing been conclusively demonstrated. Prospective data based on 
recurrence, costs, and clinical implication are needed. Never-
Anal 
theless, follow-up is required to identify recurrence and to treat 
it carly, cspecially if HPV 11 has been indcntified. 
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